Prospective, Matched Case-Control Study of Endoscopic Sleeve Gastroplasty and Semaglutide in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease at One Year.

Kumar S, Lahooti A, Hajifathalian K, Critelli B, Hassan A, Johnson KE, Baig MU, Akagbosu C, Canakis A, Hassan K, Lahooti I, Dawod Q and 7 more

Show all authors

Wong R, Buckholz A, Newberry C, Sampath K, Carr-Locke D, Mahadev S, Sharaiha RZ

Digestive diseases and sciences8 Jul 2025

PMID40629230DOI10.1007/s10620-025-09218-1PepBankPUB-40629230

Publisher page PubMedAsk about this study

Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanObservational studyEfficacy outcome
In matched adults with MASLD, semaglutide produced significantly less total body weight loss at 12 months than endoscopic sleeve gastroplasty (difference 8.29%).
In plain wordsIn adults with fatty liver disease, semaglutide led to less weight loss at 12 months than a stomach-reduction procedure (ESG).
Peptide
Semaglutide
Outcome
DecreasePercent total body weight loss (%TBWL) at 12 months versus ESG
Study
n: not reported in source
Comparator
Endoscopic sleeve gastroplasty (ESG)
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Measurements
Difference in %TBWL
8.29%
ESG minus semaglutide
Source sentences
Summary
At 12 months, in matched analysis, ESG resulted in significantly greater %TBWL than semaglutide (Diff 8.29%, p < 0.0001).
2 context sentences(design, population, supporting numbers)
Summary · context
Those treated with semaglutide or undergoing ESG with at least six months of follow-up were included.
Summary · context
Propensity score matching balanced baseline characteristics, including age, diabetes status, and initial weight.
Report a problemFND-4062923001
02HumanObservational studyEfficacy outcome
In matched adults with MASLD, ALT improvement did not differ significantly between semaglutide and endoscopic sleeve gastroplasty.
In plain wordsIn adults with fatty liver disease, the ALT liver enzyme improved similarly with semaglutide and with a stomach-reduction procedure (ESG).
Peptide
Semaglutide
Outcome
No significant changeALT improvement versus ESG
Study
n: not reported in source
Comparator
Endoscopic sleeve gastroplasty (ESG)
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated
Source sentences
Summary
ALT and AST improvements showed no significant difference between groups.
2 context sentences(design, population, supporting numbers)
Summary · context
Those treated with semaglutide or undergoing ESG with at least six months of follow-up were included.
Summary · context
Propensity score matching balanced baseline characteristics, including age, diabetes status, and initial weight.
Report a problemFND-4062923002
03HumanObservational studyEfficacy outcome
In matched adults with MASLD, AST improvement did not differ significantly between semaglutide and endoscopic sleeve gastroplasty.
In plain wordsIn adults with fatty liver disease, the AST liver enzyme improved similarly with semaglutide and with a stomach-reduction procedure (ESG).
Peptide
Semaglutide
Outcome
No significant changeAST improvement versus ESG
Study
n: not reported in source
Comparator
Endoscopic sleeve gastroplasty (ESG)
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated
Source sentences
Summary
ALT and AST improvements showed no significant difference between groups.
2 context sentences(design, population, supporting numbers)
Summary · context
Those treated with semaglutide or undergoing ESG with at least six months of follow-up were included.
Summary · context
Propensity score matching balanced baseline characteristics, including age, diabetes status, and initial weight.
Report a problemFND-4062923003
04HumanObservational studyEfficacy outcome
In matched adults with MASLD and baseline FIB-4 above 1.3, semaglutide improved FIB-4 scores significantly more than endoscopic sleeve gastroplasty.
In plain wordsIn adults with fatty liver disease and higher fibrosis scores, semaglutide improved the FIB-4 score more than a stomach-reduction procedure (ESG).
Peptide
Semaglutide
Outcome
DecreaseFIB-4 score in patients with baseline FIB-4 > 1.3 versus ESG
Study
n: not reported in source
Comparator
Endoscopic sleeve gastroplasty (ESG)
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated
Measurements
FIB-4 difference
0.89 score
semaglutide vs ESG
Source sentences
Summary
In patients with baseline FIB-4 > 1.3, semaglutide significantly improved FIB-4 scores compared to ESG (0.89, p < 0.0001).
2 context sentences(design, population, supporting numbers)
Summary · context
Those treated with semaglutide or undergoing ESG with at least six months of follow-up were included.
Summary · context
Propensity score matching balanced baseline characteristics, including age, diabetes status, and initial weight.
Report a problemFND-4062923004
05HumanObservational studyEfficacy outcome
In adults with MASLD, ALT fell significantly from baseline over one year in the semaglutide group, as it did in the ESG group.
In plain wordsIn adults with fatty liver disease, the ALT liver enzyme fell over one year with semaglutide, as it did with a stomach-reduction procedure.
Peptide
Semaglutide
Outcome
DecreaseALT change from baseline over one year
Study
n: not reported in source
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated
Source sentences
Summary
Within-group analysis showed significant ALT and AST improvements in both groups over one year, but only semaglutide significantly improved FIB-4 scores compared to baseline (Diff 0.26, p = 0.046).
2 context sentences(design, population, supporting numbers)
Summary · context
Those treated with semaglutide or undergoing ESG with at least six months of follow-up were included.
Summary · context
Propensity score matching balanced baseline characteristics, including age, diabetes status, and initial weight.
Report a problemFND-4062923005
06HumanObservational studyEfficacy outcome
In adults with MASLD, AST fell significantly from baseline over one year in the semaglutide group, as it did in the ESG group.
In plain wordsIn adults with fatty liver disease, the AST liver enzyme fell over one year with semaglutide, as it did with a stomach-reduction procedure.
Peptide
Semaglutide
Outcome
DecreaseAST change from baseline over one year
Study
n: not reported in source
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated
Source sentences
Summary
Within-group analysis showed significant ALT and AST improvements in both groups over one year, but only semaglutide significantly improved FIB-4 scores compared to baseline (Diff 0.26, p = 0.046).
2 context sentences(design, population, supporting numbers)
Summary · context
Those treated with semaglutide or undergoing ESG with at least six months of follow-up were included.
Summary · context
Propensity score matching balanced baseline characteristics, including age, diabetes status, and initial weight.
Report a problemFND-4062923006
07HumanObservational studyEfficacy outcome
In adults with MASLD, FIB-4 scores improved significantly from baseline over one year with semaglutide, but not with ESG.
In plain wordsIn adults with fatty liver disease, the FIB-4 fibrosis score improved over one year with semaglutide but not with a stomach-reduction procedure.
Peptide
Semaglutide
Outcome
DecreaseFIB-4 change from baseline over one year
Study
n: not reported in source
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated
Measurements
FIB-4 difference
0.26 score
vs baseline, semaglutide
Source sentences
Summary
Within-group analysis showed significant ALT and AST improvements in both groups over one year, but only semaglutide significantly improved FIB-4 scores compared to baseline (Diff 0.26, p = 0.046).
2 context sentences(design, population, supporting numbers)
Summary · context
Those treated with semaglutide or undergoing ESG with at least six months of follow-up were included.
Summary · context
Propensity score matching balanced baseline characteristics, including age, diabetes status, and initial weight.
Report a problemFND-4062923007

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Prospective, Matched Case-Control Study of Endoscopic Sleeve Gastroplasty and Semaglutide in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease at One Year.

Summary

Results from this study7

Version history

Subjects

Publication types

MeSH terms

Keywords